5326602025-01-012025-03-315326602025-03-315326602024-03-315326602024-04-012025-03-315326602025-01-012025-03-31in-capmkt:OtherExpenses1Member5326602025-01-012025-03-31in-capmkt:OtherExpenses2Member5326602024-04-012025-03-31in-capmkt:OtherExpenses1Member5326602024-04-012025-03-31in-capmkt:OtherExpenses2Member5326602025-01-012025-03-31RelatedPartyTransactionDomain15326602024-12-31RelatedPartyTransactionDomain15326602025-03-31RelatedPartyTransactionDomain15326602025-01-012025-03-31RelatedPartyTransactionDomain25326602024-12-31RelatedPartyTransactionDomain25326602025-03-31RelatedPartyTransactionDomain25326602025-01-012025-03-31RelatedPartyTransactionDomain35326602024-12-31RelatedPartyTransactionDomain35326602025-03-31RelatedPartyTransactionDomain35326602025-01-012025-03-31AuditorDomain15326602025-01-012025-03-31in-capmkt:AuditedMember5326602025-03-31in-capmkt:AuditedMember5326602025-01-012025-03-31in-capmkt:AdjustedMember5326602025-03-31in-capmkt:AdjustedMemberiso4217:INRiso4217:INRxbrli:shares532660VIVIMEDLABNAINE526G01021Vivimed Labs LimitedMain BoardEquity2024-04-012025-03-312025-05-302025-05-13INRMillionsQuarterlyFourth quarterSingle segmentPharma2025-05-3016:00:002025-05-3022:10:00trueCash Flow IndirectStatement on impact of audit qualificationtruetrueNoNofalsetrue2022-04-28https://www.vivimedlabs.com/wp-content/uploads/2021/09/Related-Party-Transactions-Policy.pdffalsetrue2025-01-012025-03-31AuditedStandalone225750000415200002672700001233600000-825000070730000147600004611000058930000305640000-383700000-383700000-38370000000-38370000000-38370000-3837000016583000010-0.6-0.582024-04-012025-03-31AuditedStandalone10360400004185000010778900006012300000-17860000230420000253100001863100003616500001387060000-3091700000-3091700000-309170000000-309170000000-309170000-309170000165830000103800000003.873.95other expenses64720000Items that will not be reclassified to profit or loss, net of tax-5790000other expenses367440000Items that will not be reclassified to profit or loss, net of tax-579000016583000041907000005849000000017335100009033000004349000052200001872550000311506000033645000003364500003006200001799300003932060000638951000024787200000674080000017113000003323930000587830000000039117600000564990000458010000289000006214600008304000002477750000638951000001863000000000253100000002116100006269000013760000070840000-51950000-691400004870000154910000366520000573500000000057350000005735000000000000-40590000000000000000-4059000000-405900000000002531000000-2531000000-25310000-85500000-8550000114400002890000VIVIMED LIMITED******Finoso Pharma Private Limited******SUBISIDARYSale of goods or services39170000NA391700007134000032170000VIVIMED LIMITED******Vivimed Labs USA Inc.USA******SUBISIDARYSale of goods or services3220000NA32200003320000036410000VIVIMED LIMITED******Vivimed Labs Spain SL******SUBISIDARYSale of goods or services127940000NA127940000-169440000-41500000170330000AuditedQualified opinionSVRL and COtrue2027-04-301036040000103604000013928500001392850000-309160000-309160000-3.8-3.86389520000638952000063895200006389520000584890000584890000SANTOSH VARLAWARPHANIDRANATHSIVA PRASAD JARUGULARAMA KRISHNA Ghyderabad2025-05-3037745600000000